
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure is a promising player in the oncology market with its flagship product, Optune, and multiple upcoming catalysts including potential advancement in pancreatic cancer therapies. Their strong clinical data and collaborations in the pipeline, along with anticipated FDA approvals, support our Buy rating and $46 price target through 2038. Risks to achievement include IP protection, competition, and safety or efficacy concerns, though the recently reported TRIDENT trial reaffirms the overall strong performance of TTFields therapy in glioblastoma.
Bears say
NovoCure is showing strong revenue growth from its Tumor Treating Fields (TTFields) devices, but this growth is largely driven by one-time revenue benefits and early launches of new products. Furthermore, competition from other oncology companies, particularly in the lung cancer market, may limit future growth potential. Additionally, NovoCure's financials show a decreasing trend in operating expenses, but there are still risks in the form of safety signals and regulatory concerns with their pipeline assets.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares